Cure8 research brief
Upadacitinib is an approved oral JAK1 inhibitor with evidence for inducing and maintaining remission in moderate-to-severe Crohn's disease, including colonic-predominant disease. Patients and clinicians may consider it among options for refractory disease but should weigh known JAK-related safety risks.
Adult patients with moderate-to-severe Crohn's disease (especially colonic involvement), patients who have failed prior biologic therapy, gastroenterologists, and researchers studying IBD therapeutics and biomarkers.
The article aggregates results from induction and maintenance trials showing higher clinical remission and endoscopic response with upadacitinib versus placebo, and reports sustained benefits through one year in extensions.
Real-world cohorts described in the review suggest effectiveness in patients who failed multiple prior therapies, though observational study differences limit causal conclusions.
The review also notes the safety profile aligns with known JAK inhibitor risks (notably infections including herpes zoster) and calls out a lack of validated pharmacogenetic predictors to guide individualized use.
The source is a narrative review (abstract-level content). Findings summarized are drawn from phase 2/3 trials, extension studies, and observational cohorts; heterogeneity across real-world studies and absence of validated pharmacogenetic markers limit definitive guidance on personalized use. Safety signals (eg, herpes zoster) reflect class effects requiring risk mitigation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Real-world data on upadacitinib help patients and clinicians understand how the drug performs outside clinical trials, including how long patients stay on treatment, remission rates, and common side effects.
Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug...
This study reports that upadacitinib produced clinical responses and steroid-free remission in a majority of patients with refractory Crohn's disease at 12 weeks, which may be relevant for people who have not responded...
